Pitavastatin has achieved a positive outcome from the UK Regulatory

Kowa are delighted to announce the completion of the decentralized regulatory procedure

20.07.2010

Kowa are delighted to announce that following the completion of the decentralized regulatory procedure, that their statin, pitavastatin has achieved a positive outcome from the UK Regulatory.

Wokingham, UK, 22 July 2010, Authority (MHRA) acting as the Reference Member State for 16 EU countries. Pitavastatin is indicated for the reduction of elevated total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C), in adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, and combined (mixed) dyslipidaemia, when response to diet and other non-pharmacological measures are inadequate.

Download Material

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. Find out more.

X